Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
Journal of Cutaneous Immunology and Allergy · 2023-10 · 6 (5) · 168-171
DOI: 10.1002/cia2.12302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Immunology and Allergy, online erschienen am 20.03.2023. Verfasst von Makoto Ito und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Janus kinase (JAK) inhibitors are efficacious for atopic dermatitis (AD). However, some patients receiving JAK inhibitors develop acne, especially younger patients, or herpes zoster, especially elderly patients, and desire to switch to dupilumab. We experienced two patients with immediate exacerbation of AD after switching from upadacitinib to dupilumab, and herein report these cases. This phenomenon is attributed to the difference in elimination half‐life of the two drugs and a slower onset of efficacy of dupilumab than upadacitinib. When switching from a JAK inhibitor to dupilumab, short‐term concomitant use, intensifying topical treatment, and/or rescue with cyclosporine should be considered.
Zitieren
APA
Ito, M., Kamata, M., Uchida, H., Egawa, S., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T., Ishikawa, T., & Tada, Y. (2023). Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases. Journal of Cutaneous Immunology and Allergy, 6(5), 168-171. https://doi.org/10.1002/cia2.12302
Vancouver
Ito M, Kamata M, Uchida H, Egawa S, Fukaya S, Hayashi K, et al. Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases. Journal of Cutaneous Immunology and Allergy. 2023;6(5):168-171. doi:10.1002/cia2.12302
BibTeX
@article{Ito2023,
author = {Ito, Makoto and Kamata, Masahiro and Uchida, Hideaki and Egawa, Shota and Fukaya, Saki and Hayashi, Kotaro and Fukuyasu, Atsuko and Tanaka, Takamitsu and Ishikawa, Takeko and Tada, Yayoi},
title = {Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases},
journal = {Journal of Cutaneous Immunology and Allergy},
year = {2023},
volume = {6},
number = {5},
pages = {168--171},
doi = {10.1002/cia2.12302}
}
EUVIMED